Carin Uyl De Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Professor de Groot’s research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
Yannis Natsis is Policy Manager Universal Access and Affordable Medicines. Yannis currently leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Before joining EPHA in January 2016, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the UN and the private sector in Brussels and Athens. Between 2013-2015, Yannis was Advocacy Advisor for the TransAtlantic Consumer Dialogue (TACD) focusing on access to medicines. Between 2006-2010, he was an investigative reporter for Greece’s award-winning TV news programme “Fakeli” and a contributor to the Greek daily “Kathimerini”. He has a Master’s degree in International Conflict Analysis from the University of Kent, UK and a Bachelor’s degree in European Studies from Pantion University of Social and Political Sciences, Greece. A Greek national, he is fluent in Greek, English and French.
Yannis is committed to promoting transparency, accountability and protecting the public interest in health and medicines policies. In May 2019, Yannis was appointed to the Management Board of the European Medicines Agency (EMA) by EU Member States. He is one of the two patient representatives on the Board with a 3-year mandate starting in June 2019. Since January 2018, he has been a member of the Board of the European Health Forum Gastein (EHFG) too.
Yannis is a founding member of the European Alliance for Responsible R&D and Affordable Medicines and represents the public health voice on the following groups: High Level Group (HLG) to the Round Table meetings for European Health Ministers and Heads of Europe of pharmaceutical companies; Health Technology Assessment (HTA) Network Stakeholder Pool of the European Commission.
John LaMattina was the president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and professionals in the United States, Europe, and Asia. He has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire. He’s also the author of “Drug Truths: Dispelling The Myths Of R&D” and the recently published Devalued And Distrusted: Can The Pharmaceutical Industry Restore Its Broken Image?” He is also a senior partner at PureTech Health.
Joe Damond is the Deputy Chief of Policy and Executive Vice President for International Affairs at the Biotechnology Innovation Organization (BIO), the largest service organisation for biotech companies in the world. Joe spent 12 years as a trade negotiator at the Office of the United States Trade Representative for Asia and Pacific/APEC Affairs, and is a well-respected thought-leader helping governments develop sustainable biotech ecosystems. Joe Damond received his master’s degree from Princeton University’s Woodrow Wilson School of Public and International Affairs.
Ken Redekop PhD @dontwaitforit is Editor-in-Chief for the FPM journal Health Policy and Technology and Honorary Secretary of the FPM. He is an associate professor at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.
Professor Donald Singer @HealthMed is President of the FPM. He is a Clinical Pharmacologist interested in new approaches to personalising medicine and in public understanding of health and drugs. He is a member of the panel of experts of the European Medicines Agency has been a member since 2013 of the Healthcare Professionals’ Working Party of the European Medicines Agency for which he has been involved in projects on minimizing risk from medicines. International consultancy includes advice on clinical pharmacology and safety systems for medicines as a Yale School of Medicine Faculty member within the 7 year Human Resources for Health US-AID and CDC supported programme in Rwanda. Singer is President of the UK Fellowship of Postgraduate Medicine, which publishes the Postgraduate Medical Journal (founded 1925) and Health Policy and Technology (founded 2012). He is a former Secretary of the European Association of Clinical Pharmacology and Therapeutics which supports scientific and educational exchange for over 4000 clinical pharmacologists from 34 countries. He was previously also a member of the Council of the British Pharmacological Society and Panel Member of the NIHR Health Technology Assessment Programme.